Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 6
Submit an article Journal homepage
180
Views
25
CrossRef citations to date
0
Altmetric
Original Articles: Research

Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children

Na TongDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China; ;Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China;
,
Haiyan ChuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China; ;Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China;
,
Meilin WangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China; ;Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China;
,
Yao XueDepartment of Hematology and Oncology, The Affiliated Nanjing Children’s Hospital of Nanjing Medical University, Nanjing, China;
,
Mulong DuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China; ;Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China;
,
Lingling LuDepartment of Hematology and Oncology, The Affiliated Nanjing Children’s Hospital of Nanjing Medical University, Nanjing, China;
,
Heng ZhangDepartment of Hematology and Oncology, The Affiliated Nanjing Children’s Hospital of Nanjing Medical University, Nanjing, China;
,
Feng WangDepartment of Hematology and Oncology, The Affiliated Nanjing Children’s Hospital of Nanjing Medical University, Nanjing, China;
,
Yongjun FangDepartment of Hematology and Oncology, The Affiliated Nanjing Children’s Hospital of Nanjing Medical University, Nanjing, China;
,
Jie LiDepartment of Hematology and Oncology, Soochow Children's Hospital Affiliated to Soochow University, Suzhou, China;
,
Dongmei WuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China; ;Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China;
,
Zhengdong ZhangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China; ;Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China; Correspondence[email protected]
&
Xiaojing ShengDepartment of Children’s Healthcare, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]
 show all
Pages 1436-1441 | Received 07 Jul 2015, Accepted 04 Sep 2015, Published online: 16 Nov 2015

References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.
  • Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010; 36: 277–285.
  • Terracini B. Epidemiology of childhood cancer. Environ Health 2011; 10(Suppl. 1): S8.
  • Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012; 30: 1663–1669.
  • C.S.U.W. Group. United States Cancer Statistics: 1999–2010 incidence and mortality Web-based Report. Centers for Disease Control and Prevention, and National Cancer Institute 2013; Available at: http://www.cdc.gov/uscs.
  • Weinberg RA. Tumor suppressor genes. Science 1991; 254(5035): 1138–1146.
  • Studniak E, Maloney E, Ociepa T, et al. Allelic loss of selected tumor suppressor genes in acute lymphoblastic leukemia in children. Pol J Pathol 2013; 64: 121–128.
  • Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298–1307.
  • He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447(7148): 1130–1134.
  • Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731–743.
  • Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6: 1586–1593.
  • Li L, Wu J, Sima X, et al. Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol 2013; 34: 1919–1923.
  • Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
  • Saunders MA, Liang H, Li WH. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 2007; 104: 3300–3305.
  • Agostini M, Knight RA. miR-34: from bench to bedside. Oncotarget 2014; 5: 872–881.
  • Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193–199.
  • Son MS, Jang MJ, Jeon YJ, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 2013; 524: 156–160.
  • Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923–5930.
  • Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 2011; 128: 412–417.
  • Liu YM, Wang Y, Peng W, et al. Single-nucleotide polymorphism of the pri-miR-34b/c gene is not associated with susceptibility to congenital heart disease in the Han Chinese population. Genet Mol Res 2013; 12: 2937–2944.
  • Tong N, Fang Y, Li J, et al. Methylenetetrahydrofolate reductase polymorphisms, serum methylenetetrahydrofolate reductase levels, and risk of childhood acute lymphoblastic leukemia in a Chinese population. Cancer Sci 2010; 101: 782–786.
  • Tong N, Xu B, Shi D, et al. Hsa-miR-196a2 polymorphism increases the risk of acute lymphoblastic leukemia in Chinese children. Mutat Res 2014; 759: 16–21.
  • Han Y, Pu R, Han X, et al. Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One 2013; 8(3): e58564.
  • Oh J, Kim JW, Lee BE, et al. Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep 2014; 31: 995–1002.
  • Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem 2013; 394: 415–420.
  • Zhang S, Qian J, Cao Q, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis 2014; 29: 149–154.
  • Tian Q, Jia J, Ling S, et al. A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol 2014; 40: 67–72.
  • Bensen JT, Tse CK, Nyante SJ, et al. Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control 2013; 24: 1099–1109.
  • Li L, Sima X, Bai P, et al. Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm. Clin Dev Immunol 2012; 2012: 567586.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.